The vaccines would first need to be approved or authorized for emergency use by U.S. regulators, and Pfizer says it expects to have the safety data it needs in the third week of November to file with the U.S. Food and Drug Administration.
Trump has said repeatedly that there would be a vaccine available before the election, but health officials and companies had only said that data might be available this month.
For months, Pfizer CEO Albert Bourla had maintained that the company would know this month whether its BioNTech-shared COVID-19 vaccine works.
Several drugmakers including Pfizer, AstraZeneca, Johnson & Johnson and Novavax Inc have said they expect to produce at least 1 billion doses of their vaccines next year if they get regulatory authorization. This could mean that the study will continue, with half the patients receiving placebo, after it is known that the vaccine is effective.
The Covid-19 vaccine Pfizer is developing with Germany's BioNTech will probably not be available for emergency use until after the U.S. presidential election, the company said Friday. "All the data contained in our USA application would be reviewed not only by the FDA's own scientists but also by an external panel of independent experts at a publicly held meeting convened by the agency".
United States pharmaceutical giant Pfizer expects to file for emergency use authorization for its COVID-19 vaccine in late November, around two weeks after the November 3 USA presidential election, it said Friday. Pfizer's vaccine requires two doses, about a month apart.
Bourla noted, "The timelines above reflect our best estimates of when these important milestones could be achieved". "It has said that it may have interim data on its 30,000 person trial as soon as November", as reported by Reuters.
"The preclinical results we report in this paper demonstrate the ability of MRT5500 to elicit a favorable immune response in both mice and non-human primates", Ronald Renaud, Chief Executive of Translate Bio, said.
Pfizer's announcement immediately lifted the company's shares two percent in the US.
A BioNTech spokesperson confirmed the time frame for the potential EUA application to the FDA. AstraZeneca's USA trial has been on hold since September.
However, whether the shot can safely protect people from the Covid-19 disease that has killed more than one million people worldwide will only become clear when final Phase III trials - which are ongoing outside China - are complete.
"The first batch of 60,000 vaccine doses will be produced in the near future, and the Vektor Centre will launch post-registration clinical trials in a number of Russian regions involving 40,000 volunteers".